209 related articles for article (PubMed ID: 21878358)
41. Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression.
Martin B; Shin YK; White CM; Ji S; Kim W; Carlson OD; Napora JK; Chadwick W; Chapter M; Waschek JA; Mattson MP; Maudsley S; Egan JM
Diabetes; 2010 May; 59(5):1143-52. PubMed ID: 20150284
[TBL] [Abstract][Full Text] [Related]
42. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
43. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
[TBL] [Abstract][Full Text] [Related]
44. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.
Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V
Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946
[TBL] [Abstract][Full Text] [Related]
45. Atypical nuclear localization of VIP receptors in glioma cell lines and patients.
Barbarin A; Séité P; Godet J; Bensalma S; Muller JM; Chadéneau C
Biochem Biophys Res Commun; 2014 Nov; 454(4):524-30. PubMed ID: 25450687
[TBL] [Abstract][Full Text] [Related]
46. VIP and PACAP effects on mouse major pelvic ganglia neurons.
Tompkins JD; Girard BM; Vizzard MA; Parsons RL
J Mol Neurosci; 2010 Nov; 42(3):390-6. PubMed ID: 20428965
[TBL] [Abstract][Full Text] [Related]
47. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
48. VIP impairs acquisition of the macrophage proinflammatory polarization profile.
Carrión M; Pérez-García S; Martínez C; Juarranz Y; Estrada-Capetillo L; Puig-Kröger A; Gomariz RP; Gutiérrez-Cañas I
J Leukoc Biol; 2016 Dec; 100(6):1385-1393. PubMed ID: 27381006
[TBL] [Abstract][Full Text] [Related]
49. CD4+ T cells in HIV infection show increased levels of expression of a receptor for vasoactive intestinal peptide, VPAC2.
Ipp H; Nkambule BB; Reid TD; de Swardt D; Bekker LG; Glashoff RH
Immunol Res; 2014 Oct; 60(1):11-5. PubMed ID: 24469917
[TBL] [Abstract][Full Text] [Related]
50. Vasoactive intestinal peptide axis is dysfunctional in patients with Graves' disease.
Carrión M; Ramos-Leví AM; Seoane IV; Martínez-Hernández R; Serrano-Somavilla A; Castro D; Juarranz Y; González-Álvaro I; Gomariz RP; Marazuela M
Sci Rep; 2020 Aug; 10(1):13018. PubMed ID: 32747757
[TBL] [Abstract][Full Text] [Related]
51. Activation of the VIP/VPAC2 system induces reactive astrocytosis associated with increased expression of glutamate transporters.
Nishimoto M; Miyakawa H; Wada K; Furuta A
Brain Res; 2011 Apr; 1383():43-53. PubMed ID: 21281617
[TBL] [Abstract][Full Text] [Related]
52. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor.
Voice JK; Dorsam G; Lee H; Kong Y; Goetzl EJ
FASEB J; 2001 Nov; 15(13):2489-96. PubMed ID: 11689474
[TBL] [Abstract][Full Text] [Related]
53. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
54. VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures.
Lamana A; Castro-Vázquez D; de la Fuente H; Triguero-Martínez A; Martínez-Hernández R; Revenga M; Villanueva-Romero R; Llamas-Velasco M; Chicharro P; Juarranz Y; Marazuela M; Sales-Sanz M; García-Vicuña R; Tomero E; González-Álvaro I; Martínez C; Gomariz RP
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955723
[TBL] [Abstract][Full Text] [Related]
55. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.
Couvineau A; Laburthe M
Br J Pharmacol; 2012 May; 166(1):42-50. PubMed ID: 21951273
[TBL] [Abstract][Full Text] [Related]
56. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
57. PACAP/VIP and receptor characterization in micturition pathways in mice with overexpression of NGF in urothelium.
Girard BM; Malley SE; Braas KM; May V; Vizzard MA
J Mol Neurosci; 2010 Nov; 42(3):378-89. PubMed ID: 20449688
[TBL] [Abstract][Full Text] [Related]
58. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
Nachtergael I; Gaspard N; Langlet C; Robberecht P; Langer I
Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
[TBL] [Abstract][Full Text] [Related]
59. VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
Tan YV; Abad C; Wang Y; Lopez R; Waschek J
Brain Behav Immun; 2015 Feb; 44():167-175. PubMed ID: 25305591
[TBL] [Abstract][Full Text] [Related]
60. VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.
Abad C; Jayaram B; Becquet L; Wang Y; O'Dorisio MS; Waschek JA; Tan YV
J Neuroinflammation; 2016 Jun; 13(1):169. PubMed ID: 27357191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
